interest in MOMENTA PHARMA

[Anonymous]

The knock on par is sustaining profitability long term. Biosimilars are the future and par has no irons in that fire. The purchase on momenta would propel us to the front of the list in that cutting edge generic space. Will Pat act before baxter labs that is the question?

When will par close the deal?

 

[Anonymous]

The knock on par is sustaining profitability long term. Biosimilars are the future and par has no irons in that fire. The purchase on momenta would propel us to the front of the list in that cutting edge generic space. Will Pat act before baxter labs that is the question?

Momenta has lovenox and nothing to lose from the court decision vs watson, and a victory
would be a huge boost going forward

 

[Anonymous]

The knock on par is sustaining profitability long term. Biosimilars are the future and par has no irons in that fire. The purchase on momenta would propel us to the front of the list in that cutting edge generic space. Will Pat act before baxter labs that is the question?

par novartis baxter who will it be??

 

[Anonymous]

Par/Strativa's name was removed from being a viable candidate when they found out the NSD-Adam gets weekly manicures and loves Elton John and Boy George

 

[Anonymous]

Momenta has lovenox and nothing to lose from the court decision vs watson, and a victory
would be a huge boost going forward

FDA guidelines for biosimilars are less strict then expected and biosimilars are expected to price better then expected acc to fiercebiotech

 

[Anonymous]

FDA guidelines for biosimilars are less strict then expected and biosimilars are expected to price better then expected acc to fiercebiotech

who in god's name wrote this? you are clueless.

The FDA guidelines are weak at best, and give no pathway to interchangeability or approval. They set out a process for dialogue with FDA, that will likely produce development programs in the tens of millions of dollars and multiple years of effort with no real guarantee of proving sameness. And that is all in addition to the absurd litigation process congress created. There is a reason that Teva, Merck, Hospira et al are going the full BLA route. It might cost more upfront, but it will be faster and more certain in the long run.

 

[Anonymous]

who in god's name wrote this? you are clueless.

The FDA guidelines are weak at best, and give no pathway to interchangeability or approval. They set out a process for dialogue with FDA, that will likely produce development programs in the tens of millions of dollars and multiple years of effort with no real guarantee of proving sameness. And that is all in addition to the absurd litigation process congress created. There is a reason that Teva, Merck, Hospira et al are going the full BLA route. It might cost more upfront, but it will be faster and more certain in the long run.

what, no way, who takes the long and more costly route

clueless are u

 

[Anonymous]

FDA guidelines for biosimilars are less strict then expected and biosimilars are expected to price better then expected acc to fiercebiotech

PAR needs a présence hère and MNTA is very attractive

 

[Anonymous]

Get over yourself, Par has no interest in this dog

 

[anonymous]

How is the work climate at Momenta? Please start a new thread.

 

[anonymous]

Not good. I 've seen some Heads, young ones, obviously incompetent.
Why do they hire them?

 

[anonymous]

Yep. I agree. Some of the new Directors there need to be moved. Some of them have connections with upper level. Their incompetent but what do you expect?